{"Objectives": [0], "To": [1], "update": [2], "the": [3, 7, 25, 28, 41, 93, 160, 216, 297], "EULAR": [4], "recommendations": [5, 264, 292], "for": [6, 27, 145, 163, 179, 268, 284], "management": [8, 298], "of": [9, 40, 46, 61, 65, 75, 95, 129, 132, 140, 176, 201, 299], "systemic": [10], "lupus": [11, 149, 236], "erythematosus": [12], "(SLE)": [13], "based": [14], "on": [15, 85, 124, 296], "emerging": [16], "new": [17], "evidence.": [18], "Methods": [19], "An": [20], "international": [21], "Task": [22, 82], "Force": [23, 83], "formed": [24], "questions": [26], "systematic": [29], "literature": [30], "reviews": [31], "(January": [32], "2018\u2013December": [33], "2022),": [34], "followed": [35], "by": [36], "formulation": [37], "and": [38, 58, 63, 69, 89, 115, 127, 135, 138, 165, 218, 223, 230, 249, 271, 303], "finalisation": [39], "statements": [42], "after": [43], "a": [44, 151], "series": [45], "meetings.": [47], "A": [48], "predefined": [49], "voting": [50], "process": [51], "was": [52], "applied": [53], "to": [54, 186, 214], "each": [55, 78], "overarching": [56, 87], "principle": [57], "recommendation.": [59], "Levels": [60], "evidence": [62, 302], "strengths": [64], "recommendation": [66], "were": [67], "assigned,": [68], "participants": [70], "finally": [71], "provided": [72, 123, 267], "their": [73], "level": [74], "agreement": [76], "with": [77, 148, 252], "item.": [79], "Results": [80], "The": [81, 290], "agreed": [84], "5": [86, 154, 191], "principles": [88], "13": [90], "recommendations,": [91], "concerning": [92], "use": [94], "hydroxychloroquine": [96], "(HCQ),": [97], "glucocorticoids": [98], "(GC),": [99], "immunosuppressive": [100], "drugs": [101], "(ISDs)": [102], "(including": [103], "methotrexate,": [104], "mycophenolate,": [105], "azathioprine,": [106, 204], "cyclophosphamide": [107], "(CYC)),": [108], "calcineurin": [109], "inhibitors": [110], "(CNIs,": [111], "cyclosporine,": [112], "tacrolimus,": [113], "voclosporin)": [114], "biologics": [116], "(belimumab,": [117], "anifrolumab,": [118], "rituximab).": [119], "Advice": [120], "is": [121, 143], "also": [122, 266], "treatment": [125], "strategies": [126], "targets": [128], "therapy,": [130], "assessment": [131], "response,": [133], "combination": [134], "sequential": [136], "therapies,": [137], "tapering": [139], "therapy.": [141], "HCQ": [142], "recommended": [144, 245], "all": [146], "patients": [147], "at": [150], "target": [152], "dose": [153], "mg/kg": [155], "real": [156], "body": [157], "weight/day,": [158], "considering": [159], "individual\u2019s": [161], "risk": [162], "flares": [164], "retinal": [166], "toxicity.": [167], "GC": [168, 220], "are": [169, 244, 265], "used": [170], "as": [171, 246, 279, 281], "\u2018bridging": [172], "therapy\u2019": [173], "during": [174], "periods": [175], "disease": [177, 217], "activity;": [178], "maintenance": [180], "treatment,": [181], "they": [182], "should": [183, 211, 225, 259], "be": [184, 212, 226, 260], "minimised": [185], "equal": [187], "or": [188, 240, 254, 257], "less": [189], "than": [190], "mg/day": [192], "(prednisone": [193], "equivalent)": [194], "and,": [195], "when": [196], "possible,": [197], "withdrawn.": [198], "Prompt": [199], "initiation": [200], "ISDs": [202], "(methotrexate,": [203], "mycophenolate)": [205], "and/or": [206], "biological": [207], "agents": [208], "(anifrolumab,": [209], "belimumab)": [210], "considered": [213, 227], "control": [215], "facilitate": [219], "tapering/discontinuation.": [221], "CYC": [222, 243], "rituximab": [224], "in": [228], "organ-threatening": [229], "refractory": [231], "disease,": [232, 273], "respectively.": [233], "For": [234], "active": [235], "nephritis,": [237], "GC,": [238], "mycophenolate": [239], "low-dose": [241], "intravenous": [242], "anchor": [247], "drugs,": [248], "add-on": [250], "therapy": [251], "belimumab": [253], "CNIs": [255], "(voclosporin": [256], "tacrolimus)": [258], "considered.": [261], "Updated": [262], "specific": [263], "cutaneous,": [269], "neuropsychiatric": [270], "haematological": [272], "SLE-associated": [274], "antiphospholipid": [275], "syndrome,": [276], "kidney": [277], "protection,": [278], "well": [280], "preventative": [282], "measures": [283], "infections,": [285], "osteoporosis,": [286], "cardiovascular": [287], "disease.": [288], "Conclusion": [289], "updated": [291], "provide": [293], "consensus": [294], "guidance": [295], "SLE,": [300], "combining": [301], "expert": [304], "opinion.": [305]}